Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-02-16
2011-11-29
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S050000, C514S051000, C514S052000, C514S045000
Reexamination Certificate
active
08067392
ABSTRACT:
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
REFERENCES:
patent: 4600573 (1986-07-01), Lin et al.
patent: 4789666 (1988-12-01), Gennari
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5470838 (1995-11-01), von Borstel
patent: 5583117 (1996-12-01), von Borstel et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5736531 (1998-04-01), von Borstel et al.
patent: 5906996 (1999-05-01), Murphy
patent: 5968914 (1999-10-01), von Borstel et al.
patent: 5981601 (1999-11-01), Nagley et al.
patent: 6258795 (2001-07-01), Von Borstel et al.
patent: 6316426 (2001-11-01), von Borstel et al.
patent: 6472378 (2002-10-01), von Borstel
patent: 2001/0005719 (2001-06-01), Von Borstel
patent: 2002/0028787 (2002-03-01), Watkins et al.
patent: 2004/0224920 (2004-11-01), Naviaux
patent: 2 339 008 (2000-02-01), None
patent: 0 462 075 (1991-12-01), None
patent: 817 877 (1959-08-01), None
patent: 817 877 (1959-08-01), None
patent: 1297398 (1972-11-01), None
patent: 62-12794 (1987-01-01), None
patent: 4-243830 (1992-08-01), None
patent: 7-228535 (1995-08-01), None
patent: 10-505578 (1998-06-01), None
patent: WO 86/03678 (1986-07-01), None
patent: WO 94/26761 (1994-11-01), None
patent: WO 96/14063 (1996-05-01), None
patent: WO 97/45127 (1997-12-01), None
patent: WO 97/45127 (1997-12-01), None
patent: WO 00/06174 (2000-02-01), None
patent: WO 00/50043 (2000-08-01), None
Leonard et al. Diseases of the Colon & Rectum (2006), vol. 49, pp. 407-410.
European Patent Office Examination Report, European Patent Application No. 02 759 363.1, dated Apr. 28, 2011 (10 pgs).
Database FSTA [Online], International Food Information Service (IFIS), Frankfurt-Main, DE; Klostermeyer, H., et al; “Recent knowledge about the non-protein-nitrogen content of milk. (translated) TIOL- Neuere Kenntnisse ueber den NPN-Gehalt der Milch.”; Database accession No. FS-1983-05-P-0701 (1981). D3.
Awad, Sherif, et al; “Short-term starvation and mitochondrial dysfunction—A possible mechanism leading to postoperative insulin resistance”;Clinical Nutrition, vol. 28, pp. 497-509 (2009). D4.
U.S. Appl. No. 60/121,588, filed Feb. 23, 1999, Naviaux, Robert K.
Page, Theodore, et al; “Developmental disorder associated with increased cellular nucleotidase activity”;Proceedings of the National Academy of Science USA, vol. 94, No. 21, pp. 11601-11606 (1997).
Przyrembel, J.;Inher. Metab. Dis., vol. 10, pp. 129-146 (1987).
Sengers et al;Eur. J. Pediatr., vol. 141, pp. 192-207 (1984).
Unfavorable Opinion in Portuguese, and Informal Translation of the Unfavorable Opinion; Brazil—Patent Application No. PI9913319-9, filed Aug. 31, 1999 (3 pgs).
Wochenschr, W.K.; “Diagnosis and therapy of mitochondriopathies”;PubMed—indexed for MEDLINE; vol. 109, No. 3; pp. 93-99 (1997) D1.
Bodnar, A.G., et al; “Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication”;Biochem. J; vol. 305; pp. 817-822 (1995) D2.
Dykens, J.A.; “Isolated Cerebral and Cerebellar Mitochondria Produce Free Radicals when Exposed to Elevated Ca2+and Na+: Implications for Neurodegeneration”;Journal of Neurochemistry; vol. 63; pp. 584-591 (1994) D5.
Zeviani, M., et al; “Mitochondrial disorders”;Molecular Human Reproduction; vol. 3, No. 2; pp. 133-148 (1997) D6.
Official Action issued in corresponding Japanese Patent Application No. 2000-567085, dated Dec. 18, 2009 with English translation (19 pgs).
Schapira, A.H.V.; “Mitochondrial dysfunction in neurodegenerative disorders”;Biochimica et Biophysics Acta, 1366, pp. 225-233 (1998).
Schapira, A.H.V.; “Human complex I defects in neurodegenerative diseases”;Biochemica et Biophysics Acta, 1364, pp. 261-270 (1998).
Watmough, N.J., et al; “Tissue Specific Defect of Complex I of the Mitochondrial Respiratory Chain”;Biochemical and Biophysical Research Communications; vol. 160, No. 2, pp. 623-627 (1989).
DiMauro, S., et al; “Mitochondria in neuromuscular disorders”;Biochima et Biophysics Acta, 1366, pp. 199-210 (1998).
De Vivo, D.C.; “The expanding clinical spectrum of mitochondrial diseases”;Brain&Development, vol. 15, pp. 1-22 (1993).
Tanaka, J., et al; “Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2”;PubMed Result; 2 pgs; (Mar. 29, 2009).
Murray, R., et al; DI Translation of, “Diseases Associated with Metabolism Disorder of Pyrimidines (Table 35.3)”;Biokchimia Cheloveka, M.: MIR, vol. 2; pp. 31-33 (1993).
Zaprudnov, A.M.; Translation of “Reye's Syndrome in Childhood”, p. 9, 4thfull paragraph; pp. 8-27 (1997).
Office Communication issued in corresponding European Application No. 02-759-363.1-1216, dated Jul. 8, 2009 (7 pgs).
Office Action issued in corresponding Korean Patent Application No. 2007-7017066, dated Oct. 19, 2007 with English translation (10 pgs).
Bodnar, A.G., et al; “Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication”;Biochem. J.; 305, pp. 817-822 (1995).
Office Action issued by European Patent Office Communication pursuant to Article 96(2) EPC; European Patent Application No. 99 968 207.3-2123 dated Aug. 24, 2007 (6 pgs).
Cacabelos, R., et al; “Therapeutic Effects of CDP-Choline in Alzheimer's Disease Cognition, Brain Mapping, Cerebrovascular Hemodynamics, and Immune Factors”;Annals New York Academy of Sciences; The Neurobiology of Alzheimer's Disease; pp. 399-403 (1996) XP008065562.
Pecori, J., et al; “Systemic administration of a neurotrophic drug in the complementary treatment of glaucomatous optic neuropathy”;New Trends in Ophthalmology; vol. IX, No. 2; pp. 85-91 (1994) XP008065559.
Secades et al.; CDP-Choline: Pharmacoligical and Clinical Review. Methods and Findings in Experimental and Clinical Pharmacology. Oct. 1995, vol. 17, Supplement 1, pp. 1-54.
Database Medline on STN AN 94049698, Keilbaugh et al. Anti-human Immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′, 3′-dideoxy cytidine toxicity in PC 12 cells, a neuronal model, by uridine and pyruvate. Molecular Pharmacology. Oct. 1993. vol. 44. No. 4. pp. 702-706.
Dykens, J.A. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: Implications for neurodegeneration. Journal of Neurochemistry. 1994, vol. 63, pp. 584-591.
Bodnar et al. Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochem. J. 1995, vol. 305, pp. 817-822.
Vary, “Increased pyruvate dehydrogenase kinase activity in response to sepsis”, Am. J. Physiol. (May 1991; 160 (5 Pt 1): E669-74.
Naviaux, R.K., Pending claims from U.S. Appl. No. 09/889,251, filed Nov. 1, 2001 (5 pgs).
DiMauro, S., et al; “Mitochondrial Encephalomyopathies: Where Next?”;1999 Revista De Neurologia; vol. 28, No. 2; pp. 164-158.
Luft, R., “The development of mitochondrial medicine”;Proc. Natl. Acad. Sci.; vol. 91, pp. 8731-8738 (1994).
Beal, M.F., “Mitochondrial dysfunction in neurodegenerative diseases”;Biochimica et Biophysica Acta; 1366, pp. 211-223 (1998).
Blass, J.P., “Brain Metabolism and Brain Disease: Is Metabolic Deficiency the Proximate Cause of Alzheimer Dementia?”;Journal of Neuroscience Research; vol. 66; pp. 851-856 (2001).
Bowling, A.C., et al; “Bioenergetic and Oxidative Stress in Neurodegenerative Diseases”;Life Sciences, vol. 56, No. 14, pp. 1151-1171 (1995).
Beal, M.F., “Mitochondria, free radicals, and neurodegeneration”;Current Opinion in Neurobiology; vol. 6, pp. 661-666 (1996).
Browne, S.E., et al; “Oxi
Lewis Patrick
Nixon & Vanderhye
Wellstat Therapeutics Corporation
LandOfFree
Compositions and methods for treatment of mitochondrial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of mitochondrial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of mitochondrial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293287